for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Biogen Says U.S. FDA Decision On Aducanumab Would Influnce Other Regulators: Conf. Call

Oct 21 (Reuters) - Biogen Inc:

* BIOGEN INC CEO SAYS UPCOMING FDA PANEL MEETING FOR ADUCANUMAB IS CO’S HIGHEST PRIORITY: CONF. CALL

* BIOGEN CEO EXPECTS SALES GROWTH OF MUSCLE-DISEASE DRUG SPINRAZA TO CONTINUE DESPITE INCREASED COMPETITION: CONF. CALL

* BIOGEN CFO SAYS DIVERTING SOME TECFIDERA RESOURCES TOWARDS LAUNCH OF MS DRUG VUMERITY AND ALZHEIMER’S THERAPY ADUCANUMAB

* BIOGEN CFO SAYS TECFIDERA GENERIC RIVALS PRICED AT DISCOUNT OF ABOUT 90% ON AVERAGE: CONF. CALL

* BIOGEN CEO SAYS U.S. FDA DECISION ON ADUCANUMAB WOULD INFLUENCE DECISION BY OTHER REGULATORS: CONF. CALL

* BIOGEN EXECUTIVE SAYS IF ADUCANUMAB NOT APPROVED, CO WOULD BE OBLIGATED TO RECONSIDER COST-BASE Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up